Nuformix plc (LON:NFX – Get Free Report) fell 12.7% during trading on Tuesday . The stock traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). 16,142,512 shares were traded during trading, a decline of 74% from the average session volume of 62,608,598 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Up 11.7 %
The firm has a 50 day moving average of GBX 0.05 and a 200 day moving average of GBX 0.10. The firm has a market cap of £548,937.70, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- What Are Dividend Achievers? An Introduction
- Oracle Announces Game-Changing News for the AI Industry
- How to Invest in Blue Chip Stocks
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Technology Stocks Explained: Here’s What to Know About Tech
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
